STOCK TITAN
  1. Home
  2. News
  3. IFRX

InflaRx N.V. - IFRX STOCK NEWS

Welcome to our dedicated page for InflaRx N.V. news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on InflaRx N.V. stock.

InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing inhibitors using C5a technology, primarily in Germany and the United States. The company focuses on targeting the complement activation factor known as C5a, an inflammatory mediator linked to various autoimmune and inflammatory diseases.

InflaRx's lead product candidate is vilobelimab (formerly known as IFX-1), a first-in-class, intravenously delivered anti-C5a monoclonal antibody. Vilobelimab has completed Phase IIb clinical trials for treating hidradenitis suppurativa, a rare and chronic inflammatory skin disease, as well as for ANCA-associated vasculitis, a life-threatening autoimmune condition, and pyoderma gangrenosum, a chronic inflammatory skin disorder. Additionally, the company is exploring vilobelimab’s potential in treating oncological diseases.

InflaRx is also developing IFX-2, another anti-inflammatory and autoimmune disease treatment currently in pre-clinical development. The company’s proprietary C5a/C5aR technology enables the creation of potent and specific inhibitors, positioning InflaRx as a pioneer in this niche therapeutic area.

The company has established a co-development agreement with Beijing Defe, enhancing its research and development capacity. InflaRx's innovative therapies aim to significantly improve patient outcomes in diseases with substantial unmet medical needs.

News

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Rhea-AI Summary
InflaRx N.V. (Nasdaq: IFRX) announces positive topline results from the MAD part of the Phase I trial for INF904, an orally administered low molecular weight C5aR inhibitor. INF904 demonstrated favorable pharmacokinetic and pharmacodynamic data, well tolerated with no safety concerns, and achieved ≥90% blockade of C5a-induced neutrophil activation over the 14-day dosing period. InflaRx plans to advance INF904 into Phase II clinical development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.37%
Tags
clinical trial
-
News

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

Rhea-AI Summary
InflaRx N.V. has initiated a Phase III study to investigate the efficacy and safety of vilobelimab in treating ulcerative pyoderma gangrenosum (PG), a rare and debilitating autoimmune skin disease. The study aims to enroll patients worldwide and has received Fast Track and Orphan Drug designations from regulatory authorities in the U.S. and Europe. The primary endpoint of the study is complete closure of the target ulcer within 26 weeks of treatment initiation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
clinical trial
-
News

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
InflaRx announces positive Phase I results for INF904, initiates Phase III trial for vilobelimab, and submits MAA for septic ARDS treatment. Commercial sales of Gohibic recorded. Cash and marketable securities of €113 million expected to fund operations until 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
earnings
News

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

Rhea-AI Summary
InflaRx announces positive results from Phase I trial of INF904, demonstrating excellent safety and tolerability profile, favorable PK and PD profiles, and potential for long-term treatment of chronic inflammatory conditions. INF904 achieved ≥90% blocking of C5a-induced neutrophil activation at disease relevant C5a levels. Company to present results from ongoing multiple ascending dose (MAD) part of the study in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.36%
Tags
clinical trial
-
News

InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

Rhea-AI Summary
InflaRx submits MAA for vilobelimab, EMA validates and reviews it. Submission based on PANAMO Phase III trial data showing 23.9% reduction in mortality. EUA received in the US. Company to attend upcoming scientific and investor events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.89%
Tags
covid-19
-
News

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

Rhea-AI Summary
InflaRx N.V. announced financial results for Q2 2023 and provided an operating update. The company highlighted the EUA and commercial launch of Gohibic (vilobelimab) in the US, progress in clinical development of vilobelimab in other indications, addition of Camilla Chong as Chief Medical Officer, and a cash position of €115.2 million. They also provided updates on the development of vilobelimab in pyoderma gangrenosum and cutaneous squamous cell carcinoma, as well as the progress of their oral C5aR inhibitor INF904.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.59%
Tags
earnings
News

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.02%
Tags
management
-
News

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

Rhea-AI Summary
InflaRx announces the commercial launch of Gohibic (vilobelimab) in the U.S. for the treatment of critically ill COVID-19 patients under an Emergency Use Authorization (EUA) granted by the FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
covid-19
-
News

WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients

Rhea-AI Summary
WuXi Biologics partners with InflaRx for manufacturing COVID-19 treatment Gohibic (vilobelimab)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
partnership covid-19
News

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.46%
Tags
earnings

FAQ

What is the current stock price of InflaRx N.V. (IFRX)?

The current stock price of InflaRx N.V. (IFRX) is $2.24 as of December 20, 2024.

What is the market cap of InflaRx N.V. (IFRX)?

The market cap of InflaRx N.V. (IFRX) is approximately 127.8M.

What is InflaRx N.V.'s primary focus?

InflaRx N.V. focuses on discovering and developing inhibitors using C5a technology to treat autoimmune and inflammatory diseases.

What is vilobelimab?

Vilobelimab, formerly known as IFX-1, is InflaRx's lead product candidate, an anti-C5a monoclonal antibody designed to treat various inflammatory conditions.

Which diseases is vilobelimab being developed to treat?

Vilobelimab is being developed to treat hidradenitis suppurativa, ANCA-associated vasculitis, pyoderma gangrenosum, and oncological diseases.

What is the status of IFX-2?

IFX-2 is currently in the pre-clinical development stage and is aimed at treating chronic inflammation and autoimmune diseases.

Where does InflaRx operate?

InflaRx operates primarily in Germany and the United States.

What is C5a?

C5a is a complement activation factor and inflammatory mediator involved in a variety of autoimmune and inflammatory diseases.

Does InflaRx have any partnerships?

Yes, InflaRx has a co-development agreement with Beijing Defe to enhance its research and development efforts.

What technology does InflaRx use for its products?

InflaRx uses proprietary anti-C5a/C5aR technology to develop potent and specific inhibitors for inflammatory diseases.

What are the potential benefits of InflaRx's treatments?

InflaRx's treatments aim to provide significant improvements in patient outcomes for diseases with high unmet medical needs.

How does InflaRx's lead product candidate work?

Vilobelimab works by selectively binding to free C5a, inhibiting its role as an inflammatory mediator, thereby reducing inflammation and disease progression.

Stock IFRX logo
InflaRx N.V.

Nasdaq:IFRX

IFRX Rankings

#4217 Ranked by Market Cap
N/A Ranked by Dividends

IFRX Stock Data

127.78M
54.56M
7.34%
22.52%
0.41%
Biotechnology
Healthcare
Link
United States of America
Jena